AU2017325986B2 - Metabolite biomarkers for diseases associated with the contact activation system - Google Patents

Metabolite biomarkers for diseases associated with the contact activation system Download PDF

Info

Publication number
AU2017325986B2
AU2017325986B2 AU2017325986A AU2017325986A AU2017325986B2 AU 2017325986 B2 AU2017325986 B2 AU 2017325986B2 AU 2017325986 A AU2017325986 A AU 2017325986A AU 2017325986 A AU2017325986 A AU 2017325986A AU 2017325986 B2 AU2017325986 B2 AU 2017325986B2
Authority
AU
Australia
Prior art keywords
metabolite
hae
subject
level
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017325986A
Other languages
English (en)
Other versions
AU2017325986A1 (en
Inventor
Ryan Faucette
Tripti GAUR
Daniel J. Sexton
Malini VISWANATHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2017325986A1 publication Critical patent/AU2017325986A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: DYAX CORP.
Application granted granted Critical
Publication of AU2017325986B2 publication Critical patent/AU2017325986B2/en
Priority to AU2024200561A priority Critical patent/AU2024200561B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Diabetes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017325986A 2016-09-16 2017-09-15 Metabolite biomarkers for diseases associated with the contact activation system Active AU2017325986B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024200561A AU2024200561B2 (en) 2016-09-16 2024-01-30 Metabolite biomarkers for diseases associated with the contact activation system

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662395770P 2016-09-16 2016-09-16
US62/395,770 2016-09-16
US201762518367P 2017-06-12 2017-06-12
US62/518,367 2017-06-12
PCT/US2017/051755 WO2018053247A1 (en) 2016-09-16 2017-09-15 Metabolite biomarkers for diseases associated with the contact activation system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200561A Division AU2024200561B2 (en) 2016-09-16 2024-01-30 Metabolite biomarkers for diseases associated with the contact activation system

Publications (2)

Publication Number Publication Date
AU2017325986A1 AU2017325986A1 (en) 2019-04-04
AU2017325986B2 true AU2017325986B2 (en) 2023-12-14

Family

ID=59974882

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017325986A Active AU2017325986B2 (en) 2016-09-16 2017-09-15 Metabolite biomarkers for diseases associated with the contact activation system
AU2024200561A Active AU2024200561B2 (en) 2016-09-16 2024-01-30 Metabolite biomarkers for diseases associated with the contact activation system

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024200561A Active AU2024200561B2 (en) 2016-09-16 2024-01-30 Metabolite biomarkers for diseases associated with the contact activation system

Country Status (12)

Country Link
US (3) US11340237B2 (enExample)
EP (1) EP3513197A1 (enExample)
JP (4) JP7225090B2 (enExample)
KR (3) KR20250030022A (enExample)
CN (2) CN117169508A (enExample)
AU (2) AU2017325986B2 (enExample)
CA (1) CA3037157A1 (enExample)
CO (1) CO2019002607A2 (enExample)
IL (2) IL314752A (enExample)
MX (2) MX2019002918A (enExample)
NZ (1) NZ792393A (enExample)
WO (1) WO2018053247A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62853B1 (sr) 2010-01-06 2022-02-28 Takeda Pharmaceuticals Co Proteini koji vezuju kalikrein plazme
PT3096798T (pt) * 2014-01-21 2021-02-25 Dyax Corp Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário
AU2015235967B2 (en) 2014-03-27 2020-10-22 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema
IL314752A (en) 2016-09-16 2024-10-01 Takeda Pharmaceuticals Co Metabolite biomarkers for diseases associated with the contact activation system
KR20250073510A (ko) 2016-09-16 2025-05-27 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커
EP3521828A1 (en) * 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
US12181462B2 (en) 2019-07-25 2024-12-31 Overture Life, Inc. Identification of viable human embryos
CN110514772A (zh) * 2019-08-09 2019-11-29 中国医学科学院基础医学研究所 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用
MX2022008649A (es) 2020-01-13 2022-09-23 Takeda Pharmaceuticals Co Inhibidores de calicreina plasmatica y sus usos para tratar episodios de angioedema hereditario pediatrico.
EP4126219A2 (en) * 2020-04-04 2023-02-08 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
CN113495137A (zh) * 2021-06-29 2021-10-12 江苏省中医院 两种代谢标志物单独或联合在制备诊断克罗恩病的试剂盒中的应用
CN117310059B (zh) * 2023-11-30 2024-02-02 中国人民解放军总医院 用于早期诊断或监测克罗恩病的血浆代谢标志物组合及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140086825A1 (en) * 2012-09-24 2014-03-27 William J. McFaul Methods and kits for assessing, modulating and treating substances affecting bodily processes
WO2015061183A1 (en) * 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT739355E (pt) 1994-01-11 2005-01-31 Dyax Corp Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
CA2488558C (en) 2002-06-07 2013-08-20 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP1711828A2 (en) 2004-01-28 2006-10-18 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
EP2177908A3 (en) 2005-10-11 2010-05-19 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
AU2007281220B2 (en) * 2006-07-31 2013-08-15 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP2069778A2 (en) 2006-08-03 2009-06-17 Numira Biosciences, Inc. Methods and compositions for identifying biomarkers
EP2102357B1 (en) 2006-10-16 2013-11-27 Bayer Intellectual Property GmbH Ltbp2 as a biomarker, therapeutic and diagnostic target
WO2008046528A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Npr3 as a biomarker, therapeutic and diagnostic target
ES2383235T3 (es) 2006-10-16 2012-06-19 Bayer Pharma Aktiengesellschaft CTGF como biomarcador , diana terapéutica y diagnóstica
WO2008046508A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Tgfb2 as a biomarker, therapeutic and diagnostic target
US20100081136A1 (en) 2006-10-16 2010-04-01 Stefan Golz Crtac as a biomarker, therapeutic and diagnostic target
WO2008046510A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
WO2008046512A1 (en) 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Prss23 as a biomarker, therapeutic and diagnostic target
FR2914066B1 (fr) * 2007-03-20 2009-05-22 Polyintell Sarl Kit d'analyse comprenant au moins deux polymeres a empreintes moleculaires et au moins un marqueur, ainsi que le procede d'analyse l'utilisant
PL2281204T3 (pl) 2008-04-29 2014-06-30 Psychemedics Corp Wieloanalitowa analiza w fazie stałej dla nadużywanych narkotyków i ich metabolitów
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
CN102667485B (zh) 2009-08-12 2015-04-22 福满代谢组技术有限公司 抑郁症的生物标记物、抑郁症的生物标记物的测定方法、计算机程序及记录介质
US20110098993A1 (en) 2009-10-27 2011-04-28 Anaxomics Biotech Sl. Methods and systems for identifying molecules or processes of biological interest by using knowledge discovery in biological data
WO2011053831A1 (en) * 2009-10-30 2011-05-05 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP2502079B1 (en) 2009-11-20 2015-01-28 Pharnext New diagnostic tools for charcot-marie-tooth disease
RS62853B1 (sr) 2010-01-06 2022-02-28 Takeda Pharmaceuticals Co Proteini koji vezuju kalikrein plazme
WO2011119772A1 (en) 2010-03-23 2011-09-29 Purdue Research Foundation Early detection of recurrent breast cancer using metabolite profiling
US20120040383A1 (en) 2010-08-12 2012-02-16 Wei Jia Methods and Kits Relating To Metabolite Biomarkers For Colorectal Cancer
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
JP5986440B2 (ja) 2012-07-05 2016-09-06 国立医薬品食品衛生研究所長 アルツハイマー病の発症を予測する方法
CN114949001A (zh) 2012-08-29 2022-08-30 加州理工学院 孤独症谱系障碍的诊断和治疗
HRP20190528T1 (hr) 2013-01-20 2019-05-17 Dyax Corp. PROCJENA, TESTOVI I LIJEČENJE POREMEĆAJA POSREDOVANIH S pKAL
IL273688B2 (en) 2013-01-20 2024-12-01 Dyax Corp Evaluation and treatment of bradykinin-mediated disorders
JP2016514141A (ja) 2013-03-14 2016-05-19 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Ｂ２−ブラジキニン受容体媒介の血管浮腫の治療方法
RU2637946C2 (ru) * 2013-03-15 2017-12-08 Интрексон Корпорейшн Борсодержащие диацилгидразины
EP2884282A1 (en) * 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
ES2825105T3 (es) 2014-04-08 2021-05-14 Metabolon Inc Obtención del perfil bioquímico de moléculas pequeñas de sujetos individuales para el diagnóstico de enfermedad y evaluación de la salud
AU2015321470B2 (en) 2014-09-22 2018-11-15 National Health Research Institutes Use of 5-methoxytryptophan as diagnostic agent of inflammatory diseases
IL305207A (en) * 2015-03-30 2023-10-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and their uses to prevent the outbreak of hereditary angioedema
IL311909B1 (en) 2015-08-13 2025-11-01 Takeda Pharmaceuticals Co Method for assesing the level of drug targeting the contact system in a subject
JP6570472B2 (ja) 2016-03-30 2019-09-04 株式会社マンダム 毛髪の損傷の評価方法
KR20250073510A (ko) 2016-09-16 2025-05-27 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커
JP7319916B2 (ja) 2016-09-16 2023-08-02 武田薬品工業株式会社 遺伝性血管性浮腫のｒｎａバイオマーカー
IL314752A (en) 2016-09-16 2024-10-01 Takeda Pharmaceuticals Co Metabolite biomarkers for diseases associated with the contact activation system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140086825A1 (en) * 2012-09-24 2014-03-27 William J. McFaul Methods and kits for assessing, modulating and treating substances affecting bodily processes
WO2015061183A1 (en) * 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers

Also Published As

Publication number Publication date
IL265199B1 (en) 2024-09-01
KR20220154245A (ko) 2022-11-21
KR102464380B1 (ko) 2022-11-07
US20190361036A1 (en) 2019-11-28
IL265199A (en) 2019-05-30
US12188948B2 (en) 2025-01-07
CO2019002607A2 (es) 2019-03-29
CA3037157A1 (en) 2018-03-22
IL314752A (en) 2024-10-01
NZ751481A (en) 2024-02-23
MX2024004195A (es) 2024-04-23
JP2019534446A (ja) 2019-11-28
MX2019002918A (es) 2019-07-18
KR102775437B1 (ko) 2025-03-05
CN109716137B (zh) 2023-07-21
JP7451791B2 (ja) 2024-03-18
US20250199014A1 (en) 2025-06-19
NZ792393A (en) 2026-01-30
AU2024200561B2 (en) 2026-01-22
WO2018053247A1 (en) 2018-03-22
KR20190053914A (ko) 2019-05-20
JP2025124816A (ja) 2025-08-26
EP3513197A1 (en) 2019-07-24
JP2023058612A (ja) 2023-04-25
JP2024059990A (ja) 2024-05-01
JP7225090B2 (ja) 2023-02-20
US11340237B2 (en) 2022-05-24
CN117169508A (zh) 2023-12-05
JP7692508B2 (ja) 2025-06-13
IL265199B2 (en) 2025-01-01
US20220365101A1 (en) 2022-11-17
CN109716137A (zh) 2019-05-03
AU2024200561A1 (en) 2024-02-15
KR20250030022A (ko) 2025-03-05
AU2017325986A1 (en) 2019-04-04
BR112019005167A2 (pt) 2019-07-02

Similar Documents

Publication Publication Date Title
AU2024200561B2 (en) Metabolite biomarkers for diseases associated with the contact activation system
AU2026201253A1 (en) Protein biomarkers for diseases associated with the contact activation system
HK40102782A (zh) 用於与接触活化系统相关的疾病的代谢产物生物标记
EP4548103A2 (en) Protein biomarkers for lanadelumab treatment
HK40102769A (zh) 用於接触活化系统相关的疾病的蛋白生物标记
BR112019005167B1 (pt) Método e kit para a análise de uma amostra

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER APPLICANT(S): DYAX CORP.

FGA Letters patent sealed or granted (standard patent)